Parkinson’s disease (PD) is typically diagnosed based on clinical exam, but there are imaging tests that are available to help in diagnosis. The most commonly known in the US is the Dopamine Transporter Scan (DaTscan), an imaging test in which a radioactive tracer, Ioflupane (123I) — which is also called DaTscan — is injected into the […]
Hospitalization can be stressful and challenging for anyone, but for people living with Parkinson’s disease (PD), a hospital stay can present unique risks. It is important for patients and their loved ones to be prepared for these situations in order to mitigate issues that may arise and have a chance at the best possible outcome. […]
How Adaptive DBS Aims to Offer More Personalized and Effective Therapy When the Food and Drug Administration (FDA) approved deep brain stimulation (DBS) for Parkinson’s disease (PD) in 2002, it revolutionized the PD treatment landscape. DBS has since become a very effective therapy for certain patients whose symptoms are no longer adequately controlled by medication […]
How Nanocarriers Overcome a Major Hurdle in Parkinson’s Treatment Delivering medications to the brain is one of the most significant challenges in modern medicine. The brain is protected by an incredibly selective shield known as the blood-brain barrier (BBB), a defense mechanism that keeps out toxins and harmful agents but also prevents many therapeutic drugs […]
What is neuromodulation and how can it be used to treat Parkinson’s disease? Medication remains the primary method of treating Parkinson’s disease (PD). However, neuromodulation, or therapies that involve the manipulation of brain circuitry, can also be very effective in controlling PD symptoms in particular clinical situations. Two current neuromodulatory techniques for PD are deep […]
Shaping the Future of Parkinson’s Treatment: Dr. Greenamyre’s Contributions and Outlook The American Parkinson Disease Association (APDA) is committed to furthering Parkinson’s disease (PD) research and proudly invests in the most promising clinicians and scientific projects focused on the discovery of the cause(s) and finding the cure(s) for PD. Our Centers for Advanced Research, along with […]
Understanding AI: A Powerful Tool in the Fight Against Parkinson’s Disease Artificial Intelligence (AI) is all around us and becoming more and more ubiquitous in many aspects of our lives, including Parkinson’s disease (PD) research and clinical care. But what exactly is AI, and how is it accelerating PD research and improving how doctors care […]
Promising New Treatments for Parkinson’s: What’s in the Clinical Trial Pipeline? There remains an urgent unmet need for Parkinson’s disease (PD) treatments that slow or halt the underlying neurodegenerative process that leads to disease progression. Much research is focused on this, with clinical trials underway. It is also critical that medications continue to be developed […]
Exploring the New Forms of Carbidopa/Levodopa with Dr. Vaou On a recent episode of APDA’s Dr. Gilbert Hosts, I spoke with Dr. Okeanis Vaou, a movement disorders specialist, about the various new formulations of carbidopa/levodopa that are available, including Crexont® and Vyalev®, among others. Carbidopa/levodopa is the mainstay of treatment for Parkinson’s disease (PD) and is […]
The American Parkinson Disease Association (APDA) has long been committed to providing the support, education, research, and community that helps everyone impacted by Parkinson’s disease (PD) live life to the fullest – a legacy that dates back to APDA’s founding in 1961, when a young woman named Sophia Esposito Maestrone sought to honor the memory […]
Simple Email Signup v2 (Salsa replacement form)
